Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

Nicoletta Tomasi Cont, Annamaria Ferrero, Fedro Alessandro Peccatori, Marta D'Alonzo, Giovanni Codacci-Pisanelli, Nicoletta Colombo, Nicoletta Biglia

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient's performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients' quality of life.

Original languageEnglish
Article number584
Journalecancermedicalscience
Volume9
DOIs
Publication statusPublished - Oct 22 2015

Fingerprint

Ovarian Neoplasms
Neoplasms
Endometrioid Carcinoma
Precision Medicine
Therapeutics
Antineoplastic Agents
Quality of Life
Drug Therapy
Ovarian epithelial cancer
Genetic Background

Keywords

  • Biological markers
  • Ovarian neoplasm
  • Personalised medicine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Medical treatment of early stage and rare histological variants of epithelial ovarian cancer. / Cont, Nicoletta Tomasi; Ferrero, Annamaria; Peccatori, Fedro Alessandro; D'Alonzo, Marta; Codacci-Pisanelli, Giovanni; Colombo, Nicoletta; Biglia, Nicoletta.

In: ecancermedicalscience, Vol. 9, 584, 22.10.2015.

Research output: Contribution to journalArticle

@article{a1b3f2432bce438ba96ea9c416c20e69,
title = "Medical treatment of early stage and rare histological variants of epithelial ovarian cancer",
abstract = "Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient's performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients' quality of life.",
keywords = "Biological markers, Ovarian neoplasm, Personalised medicine",
author = "Cont, {Nicoletta Tomasi} and Annamaria Ferrero and Peccatori, {Fedro Alessandro} and Marta D'Alonzo and Giovanni Codacci-Pisanelli and Nicoletta Colombo and Nicoletta Biglia",
year = "2015",
month = "10",
day = "22",
doi = "10.3332/ecancer.2015.584",
language = "English",
volume = "9",
journal = "ecancermedicalscience",
issn = "1754-6605",
publisher = "Cancer Intellilgence",

}

TY - JOUR

T1 - Medical treatment of early stage and rare histological variants of epithelial ovarian cancer

AU - Cont, Nicoletta Tomasi

AU - Ferrero, Annamaria

AU - Peccatori, Fedro Alessandro

AU - D'Alonzo, Marta

AU - Codacci-Pisanelli, Giovanni

AU - Colombo, Nicoletta

AU - Biglia, Nicoletta

PY - 2015/10/22

Y1 - 2015/10/22

N2 - Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient's performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients' quality of life.

AB - Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge. For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains uncertain. Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing the side effects. Furthermore, personal factors, such as the patient's performance status, should be taken into account in the management of ovarian cancer, with the aim of safeguarding the patients' quality of life.

KW - Biological markers

KW - Ovarian neoplasm

KW - Personalised medicine

UR - http://www.scopus.com/inward/record.url?scp=84960350844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960350844&partnerID=8YFLogxK

U2 - 10.3332/ecancer.2015.584

DO - 10.3332/ecancer.2015.584

M3 - Article

VL - 9

JO - ecancermedicalscience

JF - ecancermedicalscience

SN - 1754-6605

M1 - 584

ER -